XNYS
RVTY
Market cap16bUSD
Oct 08, Last price
152.16USD
1D
-0.94%
1Q
35.51%
Jan 2017
191.77%
Name
Perkinelmer Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PerkinElmer, Inc. operates as a global enterprise delivering innovative products, specialized services, and comprehensive solutions across the diagnostics, life sciences, and applied technology sectors. The company's operations are divided into two main segments: Discovery & Analytical Solutions, and Diagnostics. The Discovery & Analytical Solutions division furnishes scientists with an extensive suite of offerings, including chemical reagents, informatics platforms, and cutting-edge detection and imaging technologies. These resources are designed to accelerate research breakthroughs in the life sciences, and the segment also provides contract research and laboratory services. Additionally, it supplies analytical technologies, integrated solutions, and expert services to clients in the environmental, food, and industrial markets, aiding in the assessment and characterization of air, water, and soil quality. This segment further supports agricultural producers and food manufacturers, and delivers analytical instrumentation to a broad spectrum of industrial clients, encompassing chemical, semiconductor, electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment specializes in providing essential instruments, reagents, assay platforms, and software products for the early identification of genetic disorders, particularly during pregnancy and early childhood, as well as for infectious disease screening. Its product range facilitates the testing and detection of various genetic abnormalities and conditions, such as Down syndrome, hypothyroidism, muscular dystrophy, infertility, and diverse metabolic disorders. Moreover, this segment develops enabling technologies that support advanced genomic workflows, leveraging methods like G-protein coupled receptor (GPCR) analysis and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery research. PerkinElmer's client base is diverse, including pharmaceutical and biotechnology companies, research laboratories, academic and scientific institutions, public health organizations, private healthcare providers, medical professionals, and governmental agencies. Founded in 1937, PerkinElmer, Inc. is headquartered in Waltham, Massachusetts.
Related entities
Subsidiaries (2)
BIOSENSE TECHNOLOGIES PRIVATE LIMITED
EUROIMMUN Medizinische Labordiagnostika AG
Key people
Chief Financial Officer, Senior Vice President · since 2018
Chief Human Resource Officer, Senior Vice President · since 2016
James L. Corbett
Chief Financial Officer, Senior Vice President · since 2018
Daniel R. Tereau
Senior Vice President, Strategy and Business Development · since 2016
Tajinder S. Vohra
Senior Vice President, Global Operations · since 2015
Andrew Okun
Chief Accounting Officer, Vice President · since 2011
Joel S. Goldberg
Senior Vice President - Administration, General Counsel, Secretary · since 2008
Independent Director · since 2012
Independent Director · since 2016
Independent Non-Executive Chairman of the Board · since 2019
Independent Director · since 2016
Pascale Witz
Independent Director · since 2017
Legal address
C/O C T CORPORATION SYSTEM
155 FEDERAL ST.
SUITE 700
BOSTON, MA 02110
US
155 FEDERAL ST.
SUITE 700
BOSTON, MA 02110
US
Headquarters
77 4TH AVENUE
WALTHAM, MA 02451-7567
US
WALTHAM, MA 02451-7567
US
Previous name
EDGERTON, GERMESHAUSEN & GRIER, INC.
Previous name
EG&G, INC.
Previous name
PERKINELMER, INC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||